Combination treatment for BPH approved
Tamsulosin and dutasteride combination approved by FDA.
Combination treatment with the alpha blocker tamsulosin (Flomax, Boehringer Ingelheim) and 5-alpha reductase inhibitor dutasteride (Avodart, GSK) has received approval for a new indication: treatment of symptomatic enlarged prostate or benign prostatic hyperplasia (BPH). The approval was based on results from the CombAT (Combination of Avodart and Tamsulosin) trial which showed use of both drugs was superior to both monotherapies at 12 months and continued up through 24 months. Efficacy was measured as a reduction in the International Prostate Symptom Score (IPSS).
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
